本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Arrowhead Research Corporation

12.09
+0.01000.08%
成交量:89.60万
成交额:1,085.83万
市值:16.60亿
市盈率:-2.35
高:12.51
开:12.21
低:11.89
收:12.08
数据加载中...

公司资料

公司名字:
Arrowhead Research Corporation
交易所:
NASDAQ
成立时间:
2003
员工人数:
609
公司地址:
177 East Colorado Boulevard,Suite 700,Pasadena,California,United States
邮编:
91105
电话:
传真:
626 304 3401
简介:
Arrowhead Pharmaceuticals, Inc.最初于1989年在南达科他州注册成立,后在特拉华州重新注册成立。该公司开发药物,通过沉默疾病的基因来治疗疑难杂症。使用广泛的RNA化学组合和高效的递送模式,该公司的疗法触发RNA干扰机制,以诱导目标基因的快速、深度和持久敲低。该公司已将资源集中于在跨越多个治疗领域的多个动物模型中独家利用其高水平药理活性的疗法。

董事

名称
职位
Christopher Anzalone
Chief Executive Officer, President & Director
Adeoye Olukotun
Independent Director
Douglass Given
Board Chair
Marianne De Backe
Independent Director
Mauro Ferrari
Independent Director
Michael S. Perry
Independent Lead Director
Victoria Vakiener
Independent Director
William Waddill
Independent Director

股东

名称
职位
Christopher Anzalone
Chief Executive Officer, President & Director
Patrick O'Brien
Chief Operating Officer and General Counsel
Kenneth A. Myszkowski
Chief Financial Officer
James Hamilton
Chief of Discovery and Translational Medicine
Javier San Martin
Chief Medical Officer
Tracie Oliver
Chief Commercial Officer